May 18, 2021
RUC-4 (CeleCor Therapeutics), an investigational glycoprotein IIb/IIIa inhibitor (GPI) administered by subcutaneous injection, provides rapid and powerful platelet inhibition in patients with STEMI, according to findings from Cel-02, a phase IIa study.
Average platelet inhibition 15 minutes after the injection increased across three doses, from 77.5% with the lowest dose to 87.5% with the middle dose and 91.7% with the highest dose (
P = 0.002 for trend), Jurriën ten Berg, MD, PhD (St. Antonius Hospital, Nieuwegein, the Netherlands), reported during the virtual EuroPCR 2021.
RUC-4 was well tolerated among the 27 patients in the trial, with one injection-site reaction and two major bleeds, both related to perforation as the guidewire passed through a side branch of the radial artery.
(UPDATED) Looking once again at a question that many cardiologists considered settled, a new meta-analysis suggests that patients with stable coronary artery disease undergoing elective revascularization are at a lower risk of dying from cardiac causes over the long term when compared with patients treated with medical therapy alone.
The findings, presented today as a late-breaking clinical trial at EuroPCR 2021, and simultaneously published in the
European Heart Journal, seem to fly in the face of the randomized ISCHEMIA trial findings, published last year. In this analysis, the benefit appeared directly related to the duration of follow-up, with investigators reporting that the longer the follow-up, the lower the risk of cardiac death and spontaneous MI among those who underwent PCI or CABG surgery.
Credit: PCR
EuroPCR, taking place online from 18 to 20 May 2021, will be an opportunity for the interventional cardiovascular community to come together and benefit from interactive training with their peers. At this year s web-based event, Dr. Marie-Claude Morice will be presented with the Andreas Grüntzig Ethica Award in recognition of her contribution to training, education and clinical research in interventional cardiology.
The Andreas Grüntzig Ethica Award is presented every year to an outstanding colleague who has contributed in an extraordinary way to the PCR mission: serving the needs of every individual patient by helping the cardiovascular community to share knowledge, experience and practice. Dr. Morice, as a practitioner, researcher and mentor, is a perfect example of what PCR stands for and is a very deserving recipient of this year s award. The ceremony will take place on Thursday 20 May at 11.45 a.m. Paris time on the Main Arena channel.
April 09, 2021
Dropping aspirin soon after PCI seems to be the best strategy for preventing bleeding in high-risk patients with nonvalvular atrial fibrillation (AF), according to a landmark analysis of the RE-DUAL PCI trial.
As reported by TCTMD, RE-DUAL PCI supported moving away from a triple-therapy strategy P2Y12 inhibitor, warfarin, and aspirin in these patients in order to lessen bleeding without increasing the risk of thrombotic events.
The new data in conjunction with the rest of the available evidence, including those from AUGUSTUS, “are pretty clear that that strategy of prolonged triple therapy almost should never be used,” study co-author Deepak L. Bhatt, MD, MPH (Brigham and Women’s Hospital, Boston, MA), told TCTMD. “Our article sort of helps bring some granularity to the sort of minimum duration of aspirin that s probably needed.”